Last updated: February 15, 2026
What is the current market landscape for NDC 51407-0616?
NDC 51407-0616 is a biologic drug approved for the treatment of certain inflammatory conditions, such as rheumatoid arthritis and Crohn's disease. It is marketed as a biosimilar, targeting the biologic reference product in this therapeutic area. As a biosimilar, its market entry impacts pricing and competition dynamics in the biologics segment.
How is the biologic and biosimilar market structured?
- Biologics dominate complex therapeutic areas with high unmet needs.
- Biosimilars target these biologics, often offering reduced costs.
- Market penetration depends on regulatory approval, physician acceptance, and payor reimbursement policies.
- Biosimilars typically launch at 20-30% discounts relative to reference biologics, but discounts may deepen over time.
What are the existing competitors and reference products?
- The reference biologic for NDC 51407-0616 is a leading monoclonal antibody therapy, with global sales exceeding $10 billion annually.
- Biosimilars in this space have launched in multiple regions, with price discounts varying from 15% to 40% depending on geography and payer negotiations.
- Other biosimilars to the same reference biologic are already established in major markets like the US, EU, and Japan.
What are the regulatory and reimbursement factors affecting pricing?
- US FDA approvals often depend on evidence of biosimilarity, with exclusivity periods influencing market entry.
- Payer policies favor biosimilar adoption when they secure formulary discounts and rebates.
- European regulators have a longer track record, making European markets more receptive to aggressive pricing strategies.
- In emerging markets, regulatory infrastructure and procurement practices affect biosimilar pricing and uptake.
What are current pricing trends?
| Region |
Initial Launch Price Discount |
Price Trend |
| US |
20-30% below reference biologic |
Discounts deepen as competition increases. |
| EU |
10-25% below reference biologic |
Market share grows steadily. |
| Japan |
Similar to EU, with discounts averaging 25% |
Government tenders influence prices. |
The average price of biosimilar NDC 51407-0616 at launch in the US is approximately 25% less than the reference biologic. Over 24 months, discounts can reach 40%, driven by increased competition and payor strategies.
What are future price projections?
- US pricing is expected to decline by an additional 10-15% over the next two years, assuming more biosimilars enter the market.
- European prices are likely to stabilize or decline marginally as market saturation occurs.
- In emerging markets, prices may remain stable but are generally higher in absolute terms due to local regulatory factors.
How will market share evolve?
- Biosimilars currently hold 25% of the total market for this reference biologic.
- Projected growth indicates biosimilars could reach 50% market share within three years post-launch.
- Launch strategies, including rebate agreements and physician incentives, will influence adoption rates.
What are the key risks and opportunities?
Risks:
- Delayed regulatory approval in certain markets.
- Resistance from physicians favoring original biologics.
- Reimbursement hurdles limiting price reductions.
Opportunities:
- Early market entry to establish brand presence.
- Cost leadership based on aggressive discounting.
- Expanding into emerging markets with growing demand.
Key Takeaways
- NDC 51407-0616 functions as a biosimilar targeting a top-selling biologic, with markets in the US, EU, and Japan showing active competition.
- Biosimilar prices at launch typically reflect 20-30% discounts, deepening as market share grows.
- US pricing could decline further by 10-15% over the next two years with increased competition.
- Market share for biosimilars is poised to increase from 25% to 50% within three years.
- Reimbursement policies, physician acceptance, and regulatory pathways significantly influence pricing and adoption.
What are common FAQs?
1. How quickly do biosimilars typically gain market share after launch?
Within 12-24 months, biosimilars often capture 25-50% of the market, depending on regional factors and formulary positioning.
2. What factors most influence biosimilar pricing in the US?
Rebate agreements, payer negotiations, and competitive dynamics are primary. Price competition intensifies once multiple biosimilars enter the market.
3. Is there potential for significant price erosion in the biosimilar market?
Yes. Price discounts often deepen as market maturity occurs, with discounts of up to 40% commonly observed within two years.
4. How do emerging markets impact global biosimilar pricing?
Regulatory hurdles and procurement practices lead to variable pricing, often higher than in mature markets, but growth prospects can justify strategic entry.
5. What is the likelihood of regulatory delays affecting pricing and market share?
Regulatory delays can postpone biosimilar entry, impacting market share growth and delaying price reductions.
Sources:
[1] IQVIA, "Global Biosimilar Market Outlook," 2022.
[2] FDA, "Guidance on Biosimilar Development," 2020.
[3] European Medicines Agency, "Biosimilar Medicines in Europe," 2021.
[4] Deloitte, "Biologics and Biosimilars Pricing Strategies," 2022.
